MAPK3 and ovarian cancer: •Therapy induced hyper-activated ERK1/2 but not AKT imparts multi-drug resistance against doxorubicin, gemcitabine and etoposide (second line non-platinum agent) in acquired and intrinsically platinum resistant ovarian cancer cells.